Revolution Medicines, Inc. RVMD Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Bristol-Myers SquibbBMY

$207M+6.7%

BridgeBio PharmaBBIO

$3.32M-30.7%

Erasca, Inc.ERAS

$5.25M+9.6%

Relay Therapeutics, Inc.RLAY

$4.01M+13.9%

ArriVent BioPharma, Inc.AVBP

$99K-28.3%

Arcus BiosciencesRCUS

$13M+8.3%

FAQ

What is Revolution Medicines, Inc.'s operating lease liabilities (current)?

Revolution Medicines, Inc. (RVMD) reported operating lease liabilities (current) of $16.75M in Q2 2026.

How has Revolution Medicines, Inc.'s operating lease liabilities (current) changed year-over-year?

Revolution Medicines, Inc.'s operating lease liabilities (current) increased by 28.0% year-over-year, from $13.09M to $16.75M.

What is the long-term trend for Revolution Medicines, Inc.'s operating lease liabilities (current)?

Over 5 years (2020 to 2025), Revolution Medicines, Inc.'s operating lease liabilities (current) has grown at a 35.0% compound annual growth rate (CAGR), from $3.67M to $16.47M.

What does operating lease liabilities (current) mean?

The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.